HIGHLIGHTS & REPORT INDEX

Global Biosimilars Market to Surpass US$78.9 Billion by 2030 Amid Strong Double-Digit Growth

The global biosimilars market is estimated at approximately US$36.7 billion in 2025 and is projected to reach US$78.9 billion by 2030, advancing at a CAGR of 16.5% over the forecast period. Monoclonal antibodies (mAbs), a leading segment within the market, are expected to maintain strong momentum, registering a CAGR of 16.8% and reaching about US$37.7 billion by 2030. The growth factors and hematopoietic agents segment is also poised for steady expansion, with a projected CAGR of 15.6% during the same timeframe.

From a regional perspective, the U.S. biosimilars market is estimated at US$13.8 billion in 2025. China, the world’s second-largest economy, is forecast to grow rapidly, reaching nearly US$6.8 billion by 2030 at a CAGR of 18.8%. Other key markets include Japan and Canada, which are expected to grow at CAGRs of 14.9% and 17.1%, respectively. In Europe, Germany is projected to exhibit strong growth, with an estimated CAGR of around 17.9% over the forecast period.

Global Biosimilars Market – Key Trends and Drivers

How Are Biosimilars Transforming the Global Economics of Biologic Therapies?

The global biosimilars market has transitioned from a niche alternative to originator biologics into a central component of modern pharmaceutical systems, reshaping both treatment accessibility and pricing structures across key therapeutic areas. Designed to closely replicate reference biologics in safety, purity, and efficacy, biosimilars enter the market post-patent expiry, introducing much-needed competition in segments traditionally dominated by high-cost branded therapies. This transformation is particularly evident in areas such as oncology, autoimmune diseases, diabetes, inflammatory conditions, and hematology, where prolonged biologic usage has historically imposed significant financial burdens on healthcare systems. Advancements in analytical technologies, protein engineering, and cell line development have further minimized uncertainties around biosimilar comparability. At the same time, regulatory bodies across North America, Europe, and Asia-Pacific have streamlined approval pathways, accelerating product development. Consequently, biosimilars are now regarded not merely as lower-cost substitutes but as essential elements of treatment strategies, especially in cost-sensitive and hospital-driven healthcare environments.

How Are Regulatory Alignment and Clinical Confidence Driving Market Adoption?

Improved regulatory clarity and growing clinical confidence have become pivotal in accelerating biosimilar adoption across global markets. Initial concerns among healthcare providers regarding interchangeability and immunogenicity have gradually diminished, supported by expanding real-world evidence and post-marketing data. Europe, with its long-standing regulatory experience, has led the normalization of biosimilar use in clinical practice, while other regions are rapidly aligning with similar frameworks. Enhanced guidelines on indication extrapolation and pharmacovigilance have further strengthened confidence among prescribers. The increasing acceptance of switching protocols—particularly for chronic therapies—has sustained biosimilar utilization beyond initial uptake phases. Additionally, policy mechanisms such as national tender systems, reference pricing, and hospital procurement strategies have embedded biosimilars into standard care pathways. This institutional adoption has shifted competition away from promotional intensity toward factors such as manufacturing reliability, consistent supply, and value-added clinical support, reinforcing long-term market penetration.

How Do Manufacturing Scale and Supply Chain Strategies Influence Market Evolution?

Manufacturing scale and operational efficiency have emerged as decisive factors in determining competitiveness within the biosimilars market. The complexity of biosimilar production—requiring advanced bioprocessing, rigorous validation, and stringent quality control—demands substantial capital investment, favoring established biologics players and well-funded entrants. Technological advancements in upstream and downstream processing have improved production yields and consistency, enabling more predictable cost structures and competitive pricing. Simultaneously, manufacturers are diversifying global supply chains by establishing multi-regional production facilities to mitigate risks associated with regulatory changes, geopolitical uncertainties, and logistics disruptions. This strategic diversification ensures continuity of supply in high-demand therapeutic segments such as oncology and immunology, where treatment interruptions can have critical consequences. As production platforms mature, companies are increasingly leveraging shared infrastructure to support multiple biosimilar products, accelerating development timelines and strengthening portfolio depth, thereby enhancing overall market sustainability.

What Key Forces Are Accelerating Biosimilars Demand Worldwide?

The sustained growth of the biosimilars market is driven by a combination of clinical demand, economic pressures, and evolving stakeholder behavior. The rising incidence of chronic and life-threatening diseases has significantly expanded the patient population requiring biologic therapies, particularly in oncology, autoimmune disorders, and metabolic conditions. Concurrently, mounting pressure on healthcare budgets—both public and private—has intensified the need for cost-effective treatment alternatives, positioning biosimilars as a preferred solution in reimbursement-driven systems. Physician prescribing patterns have also evolved, with increasing willingness to initiate treatment using biosimilars rather than reserving them for later-stage switching. Patient acceptance has grown in parallel, supported by consistent clinical outcomes and improved affordability. Furthermore, expanding healthcare infrastructure in emerging markets has created new avenues for biologic adoption, where biosimilars often serve as the primary entry point for advanced therapies. Collectively, these factors continue to drive robust demand and deepen the integration of biosimilars into global healthcare systems.

SCOPE OF STUDY

The report analyzes the Biosimilars market by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues, Other Drug Classes); Distribution Channel (Hospitals, Specialty Pharmacies, Other Distribution Channels; Application (Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application, Other Applications).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

SELECT PLAYERS:

Abbott Laboratories; Amgen Inc. ; Biocon Ltd.; Biogen, Inc. ; Bio-Thera Solutions, Ltd.; Boehringer Ingelheim International GmbH; Celltrion, Inc.; Dr. Reddy`s Laboratories Ltd.; Eli Lilly and Company; Fresenius Kabi AG; Gedeon Richter PLC ; Intas Pharmaceuticals Ltd.; Pfizer, Inc.; Samsung Bioepis; Sandoz Group AG ; STADA Arzneimittel AG; Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I.   METHODOLOGY

Research design & approach

Primary research

Secondary research

Data sources & validation

Forecasting methodology

Market sizing models and growth rate assumptions

Definitions and terminology

I.   EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Biosimilars: Driving the Shift from Market Exclusivity to Affordable, Equitable Access

Biosimilars Explained: Core Concepts and Fundamentals

Biosimilar Nomenclature and Classification

Evolution and Historical Development of Biosimilars

The Scientific Foundations of Modern Biologic Therapies

Biosimilars vs. Originator Biologics: Key Differences

Biosimilars vs. Generic Drugs: Distinctions That Matter

Inside the Biosimilar Development Lifecycle

Regulatory Approval Pathways for Biosimilars in the United States

The Role of the World Health Organization (WHO) in Advancing Biosimilars Adoption

Key Benefits and Value Proposition of Biosimilars

Global Economy at an Inflection Point in 2026: Slower Growth Becomes the New Baseline

EXHIBIT: Policy-Driven Disruptions Reshape Trade, Capital Flows, and Growth, With Fragmentation Emerging as a Structural Risk: Global GDP Growth Trends (Annual % Change) for 2024–2026

EXHIBIT: Inflation Remains Under the Spotlight as Tariff Volatility Rekindles Price Pressures Across Markets: Global Inflation Trends (%) from 2019 to 2026

EXHIBIT: Oil Prices as a Key Economic Indicator—Tracking Global Stability and Downturn Signals: Average Annual Brent Crude Prices (US$ per Barrel), 2019–2026

Assessing the Impact of U.S. Tariff Policies Under Trump: Market Implications and Uncertainty

Global Market Outlook

Key Growth Drivers, Emerging Trends, and Market Challenges at a Glance

Monoclonal Antibodies: The Leading Segment in Biosimilars

Oncology and Autoimmune/Inflammatory Diseases Dominate Key Indications

Developed Markets Lead Adoption While Emerging Economies Fuel Long-Term Expansion

Competitive Landscape

Global Market Share of Leading Biosimilars Players (2025E)

Competitive Positioning of 46 Key Companies: Strong / Active / Niche / Trivial (2025E)

Recent Industry Developments

Insights from Industry Experts

2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS

Biotechnological Breakthroughs Driving the Next Wave of Biosimilars Expansion

The Biologics Patent Cliff: Expiring Blockbusters Unlock New Growth Avenues for Biosimilars

EXHIBIT: Timeline of Patent Expirations for Leading Biologic Drugs

Faster Regulatory Approvals Enabling Scaled Commercialization of Biosimilars

EXHIBIT: FDA and EMA Biosimilar Approvals (2016–2025)

EXHIBIT: FDA Biosimilar Approvals by Therapeutic Area (%) – 2025

EXHIBIT: U.S. FDA-Approved Biosimilars and Follow-On Biologics

EXHIBIT: EMA-Approved Biosimilars in Europe

EXHIBIT: Biosimilars Refused or Withdrawn by EMA

EXHIBIT: Biosimilars Under EMA Review for Marketing Authorization

Rising Burden of Chronic Diseases Fueling Demand for Affordable Biosimilars

EXHIBIT: Global Economic Burden of Chronic Diseases (US$ Trillion): 2018 vs. 2030

EXHIBIT: Global Cancer Incidence and Mortality by Type (2022)

EXHIBIT: Global Diabetes and Population Trends (2000, 2011, 2024, 2050)

EXHIBIT: Cardiovascular Disease Fatalities by Condition (Percentage Breakdown)

Growing Global Biologics Spending Elevates the Importance of Cost-Effective Alternatives

EXHIBIT: Pharmaceutical Spending as a Share of Healthcare Expenditure (Select Countries)

Healthcare Cost Pressures Accelerating the Transition Toward Biosimilars

EXHIBIT: Healthcare Spending as % of GDP Across Key Markets

Evolving Regulatory Frameworks Strengthening the Case for Biosimilar Development

EXHIBIT: Key Regulatory Policies Influencing the Biosimilars Market

From Volume to Value: Personalized Medicine Reshaping Biosimilars Strategies

EXHIBIT: Global Personalized Medicine Market Size (US$ Billion): 2024–2030

Interchangeability: Redefining Competitive Dynamics in the Biosimilars Landscape

Advancements in Manufacturing Processes Enhancing Quality, Efficiency, and Consistency

Next-Generation Biosimilar Formulations: Bridging Science, Regulation, and Patient Experience

Scalability as a Critical Pillar of Biosimilar Manufacturing

Advances in Cell Culture and Purification Technologies Driving High-Quality Production

Investment Momentum Accelerating Innovation and Market Expansion

The Role of Advanced Analytics in Streamlining Biosimilar Regulatory Approvals

Artificial Intelligence Transforming Biosimilar Development and Commercialization

Rapid Growth of Biosimilars Across Asian Healthcare Markets

Key Challenges Impacting the Global Biosimilars Markets

4. GLOBAL MARKET PERSPECTIVE

World Biosimilars Market Analysis of Annual Revenues in US$ Million for Years 2018 through 2030

World Recent Past, Current & Future Assessment for Biosimilars by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Biosimilars by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Biosimilars by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Monoclonal Antibodies (mAbs) by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Monoclonal Antibodies (mAbs) by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Monoclonal Antibodies (mAbs) by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Growth Factors / Hematopoietic Agents by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Growth Factors / Hematopoietic Agents by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Growth Factors / Hematopoietic Agents by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Insulins / Analogues by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Insulins / Analogues by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Insulins / Analogues by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Other Drug Classes by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Other Drug Classes by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Other Drug Classes by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Hospitals by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Hospitals by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Hospitals by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Specialty Pharmacies by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Specialty Pharmacies by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Specialty Pharmacies by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Other Distribution Channels by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Other Distribution Channels by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Other Distribution Channels by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Autoimmune Disorders Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Autoimmune Disorders Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Autoimmune Disorders Application by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Oncology Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Oncology Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Oncology Application by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Hematology Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Hematology Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Hematology Application by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Endocrinology Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Endocrinology Application by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Endocrinology Application by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Assessment for Other Applications by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

World Historic Analysis for Other Applications by Geographic Region – USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

World 12-Year Outlook for Other Applications by Geographic Region – Percentage Distribution of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

Global 13-Year Perspective for Other Applications by Region – Percentage Share of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East, and Africa for 2017, 2025, and 2030

III.   MARKET ANALYSIS

UNITED STATES

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

USA 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

USA Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

USA 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

USA Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

USA Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

USA 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Canada 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Canada Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Canada 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Canada Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Canada Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Canada 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

JAPAN

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Japan 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Japan Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Japan 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Japan Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Japan Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Japan 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

CHINA

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in China for 2025 (E)

China Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

China 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

China Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

China 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

China Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

China Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

China 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

EUROPE

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Assessment for Biosimilars by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2024 through 2030 and % CAGR

Europe Historic Analysis for Biosimilars by Geographic Region – France, Germany, Italy, UK and Rest of Europe Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Europe 12-Year Outlook for Biosimilars by Geographic Region – Percentage Distribution of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2025 & 2030

Europe Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Europe 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Europe Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Europe 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Europe Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Europe Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Europe 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

FRANCE

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in France for 2025 (E)

France Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

France 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

France Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

France 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

France Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

France Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

France 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

GERMANY

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Germany 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Germany Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Germany 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Germany Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Germany Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Germany 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Italy 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Italy Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Italy 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Italy Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Italy Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Italy 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

UNITED KINGDOM

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

UK 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

UK Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

UK 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

UK Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

UK Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

UK 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Rest of Europe 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Rest of Europe Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Rest of Europe 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Rest of Europe Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Rest of Europe 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years

ASIA-PACIFIC

Biosimilars Market Presence – Strong/Active/Niche/Trivial – Leading Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Asia-Pacific 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Asia-Pacific 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Asia-Pacific 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Assessment for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Analysis for Biosimilars by Drug Class – Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Rest of World 12-Year Outlook for Biosimilars by Drug Class – Percentage Distribution of Value Revenues for Monoclonal Antibodies (mAbs), Growth Factors / Hematopoietic Agents, Insulins / Analogues and Other Drug Classes for the Years 2018, 2025 & 2030

Rest of World Recent Past, Current & Future Assessment for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Analysis for Biosimilars by Distribution Channel – Hospitals, Specialty Pharmacies and Other Distribution Channels Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Rest of World 12-Year Outlook for Biosimilars by Distribution Channel – Percentage Distribution of Value Revenues for Hospitals, Specialty Pharmacies and Other Distribution Channels for the Years 2018, 2025 & 2030

Rest of World Recent Past, Current & Future Assessment for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications – Independent Evaluation of Annual Revenues in US$ Million for the Years 2024 through 2030 and % CAGR

Rest of World Historic Analysis for Biosimilars by Application – Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications Markets – Independent Evaluation of Annual Revenues in US$ Million for Years 2018 through 2023 and % CAGR

Rest of World 12-Year Outlook for Biosimilars by Application – Percentage Distribution of Value Revenues for Autoimmune Disorders Application, Oncology Application, Hematology Application, Endocrinology Application and Other Applications for the Years 2018, 2025 & 2030

IV.   COMPETITIVE METRICS

World market rank & share

Overview of global competition

Global market leaders vs. regional players

Regional leadership and penetration strategies

Global revenue share of top manufacturers and solution providers

Company positioning & benchmarking

Strategic mapping of key players based on product portfolio and geographic reach

Comparative benchmarking: Pricing, Technology adoption, Channel presence

Start-ups & emerging players in the Biosimilars ecosystem

Strategic competitive approaches

Innovation pipelines & new product development

Mergers, acquisitions, and strategic alliances

Market entry strategies for emerging economies

Exhibit: Biosimilars – Global key competitors’ market share in (2025)

Exhibit: Competitive positioning matrix – leaders, challengers, niche and emerging players in (2025)